Overview of HIPEC for Ovarian Cancer

HIPEC (Hyperthermic Intraperitoneal Chemotherapy) is a treatment that involves circulating heated chemotherapy directly into the abdominal cavity during or after cytoreductive surgery. This approach targets residual microscopic ovarian cancer cells on peritoneal surfaces. By using hyperthermia (heating the chemotherapy to 41-43°C), this method enhances drug penetration, effectively killing heat-sensitive cancer cells while sparing distant organs. It is particularly beneficial for patients with stage III epithelial ovarian cancer.

Types of HIPEC for Ovarian Cancer

• •Primary HIPEC
  Delivered immediately after optimal cytoreduction in patients with newly diagnosed stage III disease, using either cisplatin or mitomycin-C for 60 to 90 minutes.
• •Interval HIPEC
  Administered between cycles of neoadjuvant chemotherapy or during interval cytoreduction to improve rates of complete resection.
• •Recurrent Disease HIPEC
  Utilized for platinum-sensitive recurrences confined to the peritoneum, involving palliative cytoreduction along with HIPEC.

When HIPEC is Needed

• •After Optimal Primary Cytoreduction
  For stage III patients with no visible residual disease (less than 1 cm), HIPEC can extend overall survival by 12 to 16 months compared to surgery alone.
• •During the Neoadjuvant Treatment Pathway
  Interval HIPEC after three cycles of carboplatin-paclitaxel can shrink tumors, enabling complete resection in 60-70% of initially unresectable cases.
• •For Select Recurrent Disease
  HIPEC benefits platinum-sensitive peritoneal recurrences in patients with good performance status (ECOG 0-1) by avoiding systemic toxicity.

Treatment Process

HIPEC is performed immediately following cytoreduction under general anesthesia. The process involves abdominal lavage with 2-3 liters of heated chemotherapy solution, circulated via pumps for 90 minutes. Temperature probes maintain the solution at 41-42°C, and closed-circuit systems prevent systemic absorption. Patients typically recover in the ICU for 24-48 hours and can resume a diet by days 5-7, with a total hospital stay of 7-14 days.

Benefits of HIPEC for Ovarian Cancer

The Dutch OVHIPEC-1 trial indicated a median survival of 45 months with HIPEC compared to 33 months with cytoreduction alone. Complete resection rates increased by 20-30%, and local control reduced peritoneal recurrence by 50%, preserving quality of life for a longer period.

Side Effects and Risks

Acute complications may include prolonged ileus (30%), fistula formation (5-10%), infections (15%), and bone marrow suppression. Long-term risks include adhesions (20%), bowel obstruction, and renal toxicity, which can be mitigated by hydration and the use of amifostine.

Aftercare and Recovery

• •Post-Surgical Care
  Nasogastric decompression may be used to prevent aspiration, and early ambulation is encouraged to combat DVT during the 4-6 week recovery period.
• •Nutrition and Monitoring
  High-protein nutrition helps reverse catabolism, while monitoring CA-125 levels guides the timing of further adjuvant therapy.
• •Activity Restrictions
  Patients should maintain pelvic rest for 8 weeks; surgical scars typically heal within three months post-surgery.

Why Choose Everhope

Everhope Oncology features specialized HIPEC suites staffed by experienced surgeons specializing in peritoneal malignancies, achieving R0 resection rates greater than 80%. The center integrates molecular profiling for patient selection and IV nutritional optimization to minimize postoperative complications.